The human body hosts a complex and dynamic population of trillions of microorganisms—
the microbiota—which influences the body in homeostasis and disease, including cancer …

The therapeutic landscape of several genitourinary malignancies has been revolutionized
by the development of immune checkpoint inhibitors (ICIs); however, the utility of …

Checkpoint immunotherapy has yielded meaningful responses across many cancers but
has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7 …

Chimeric antigen receptor T cell immunotherapy has achieved promising therapeutic effects
in the treatment of hematological malignancies. However, there are still many obstacles …

Neoadjuvant therapies can improve tolerability, reduce tumor volume to facilitate surgery,
and assess subsequent treatment response. Therefore, there is much enthusiasm for …

Purpose: Uveal melanoma (UM) is the most common intraocular malignant tumor. Despite
successful treatment of the primary tumor, about 50% of patients will recur with systemic …

The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

In the ever-evolving landscape of cancer research, immuno-oncology stands as a beacon of
hope, offering novel avenues for treatment. This study capitalizes on the vast repository of …

With the high incidence of urogenital tumors worldwide, urinary system tumors are among
the top 10 most common tumors in men, with prostate cancer ranking first and bladder …

Immune checkpoints (ICs) are molecules implicated in the fine-tuning of immune response
via co-inhibitory or co-stimulatory signals, and serve to secure minimized host damage …